Vaccine efficacy against HPV 16/18-related 6-month persistent infection or CIN1 + was significant in all age groups combined ( 811 % , 977 % CI 521-940 ) , in the 26-35 years age group ( 835 % , 450-968 ) , and in the 36-45 years age group ( 772 % , 28-969 ) ; no cases were seen in women aged 46 years and older .